×
About 3,823 results

ALLMedicine™ Cutaneous T-cell Lymphoma Center

Research & Reviews  1,102 results

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Jun 24th, 2022 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

Epidermotropic cutaneous T-cell lymphoma with follicular helper T-cell phenotype limite...
https://doi.org/10.1111/1346-8138.16492
The Journal of Dermatology; Tanaka M, Miyagaki T et. al.

Jun 19th, 2022 - Epidermotropic cutaneous T-cell lymphoma with follicular helper T-cell phenotype limited to one anatomical region.|2022|Tanaka M,Miyagaki T,Sato N,Akita T,Kadono T,|

Demographic Patterns and Increasing Incidence of Cutaneous T-Cell Lymphoma in Louisiana.
https://doi.org/10.1001/jamaoncol.2022.1915
JAMA Oncology; Maghfour J, Gill F et. al.

Jun 17th, 2022 - Demographic Patterns and Increasing Incidence of Cutaneous T-Cell Lymphoma in Louisiana.|2022|Maghfour J,Gill F,Olson J,Guido N,Echuri H,|

Pralatrexate for Peripheral T-cell lymphoma (PTCL): Chance only supports the prepared m...
https://doi.org/10.2174/1871520622666220610151603
Anti-cancer Agents in Medicinal Chemistry; Altınay S, Kural A et. al.

Jun 14th, 2022 - Due to their primary effects on DNA synthesis, antimetabolites are most effective against actively dividing cells and significantly specific to the cell cycle phase. Pralatrexate (PDX), an antifolate metabolite designed to accumulate in cancer cel...

Characterization of primary cutaneous T-cell lymphoma following solid organ transplanta...
https://doi.org/10.1111/ijd.16300
International Journal of Dermatology; Shimshak S, Dai C et. al.

Jun 11th, 2022 - Immunosuppression following solid organ transplantation is a known risk factor for the development of posttransplant lymphoproliferative disorders (PTLD). Primary cutaneous T-cell lymphoma (CTCL) occurring in the posttransplant setting is rare, wh...

see more →

Guidelines  2 results

Guidelines on the use of extracorporeal photopheresis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291097
Journal of the European Academy of Dermatology and Venere... Knobler R, Berlin G et. al.

Dec 21st, 2013 - After the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown sig...

Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneo...
https://doi.org/10.1111/j.1365-2141.2011.08651.x
British Journal of Haematology; Dearden CE, Johnson R et. al.

Apr 13th, 2011 - The peripheral T-cell neoplasms are a biologically and clinically heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. Natural killer (NK) cell neoplasms are included in this group. The Wor...

see more →

Drugs  30 results see all →

Clinicaltrials.gov  154 results

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Jun 24th, 2022 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT05225584

Jun 9th, 2022 - This is an open-label Phase 1a (dose escalation)/1b (dose expansion) first-in-human study of KT-333 in adult patients. Patients with relapsed/refractory (R/R) lymphomas and solid tumors will be enrolled in Phase 1a. Phase 1b will consist of separa...

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04128072

Jun 9th, 2022 - Cutaneous T-Cell Lymphoma (CTCL) has a chronic, relapsing course with patients undergoing multiple, consecutive therapies. Treatment aims at the clearance of skin disease, minimization of recurrence, prevention of disease progression and preservat...

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
https://clinicaltrials.gov/ct2/show/NCT04652960

Jun 8th, 2022 - PRIMARY OBJECTIVE: I. To determine the recommended phase II dose (RP2D) or maximum tolerated dose (MTD) of the combination of duvelisib with nivolumab in patients with advanced mycosis fungoides/Sezary syndrome (MF/SS). SECONDARY OBJECTIVES: I. To...

Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
https://clinicaltrials.gov/ct2/show/NCT02192021

Jun 6th, 2022 - This study will evaluate a novel approach to the treatment of patches and plaques in the skin of patients diagnosed with cutaneous t-cell lymphoma utilizing a dissolvable microneedle array (MNA) delivery device that is used to directly and specifi...

see more →

News  235 results

Marking Bunn's Lifetime of Leadership in Lung Cancer Care
https://www.onclive.com/view/marking-bunns-lifetime-of-leadership-in-lung-cancer-care

Oct 6th, 2021 - Paul A. Bunn Jr, MD When Paul A. Bunn Jr, MD, arrived at the University of Colorado School of Medicine in 1984, there was no National Cancer Institute (NCI)-designated cancer center in the region. The Division of Medical Oncology had only four me...

Dr. Foss on the Unmet Need in Cutaneous T-cell Lymphoma
https://www.onclive.com/view/dr-foss-on-the-unmet-need-in-cutaneous-t-cell-lymphoma

Oct 6th, 2021 - Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, discusses the challenges faced in cutaneous T-cell lymphoma. It has been a great challenge to find effective therapies for patients with cutaneous T-cell lymphom...

Dr. Feldman Discusses Using Doxil for CTCL
https://www.onclive.com/view/dr-feldman-discusses-using-doxil-for-ctcl

Oct 6th, 2021 - Tatyana Feldman, MD, a hematologist and oncologist specializing in lymphoma at the John Theurer Cancer Center at Hackensack University Medical Center, discusses the phase II multicenter trial examining the introduction of pegylated liposomal doxor...

T-Cell Lymphoma Options Burgeoning With Ongoing Clinical Trials
https://www.onclive.com/view/tcell-lymphoma-options-burgeoning-with-ongoing-clinical-trials

Oct 6th, 2021 - Steven Horwitz, MD Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin (Adcetris) to improve outcomes for these patients. For example, the double-blind, randomized, multic...

Targeted PD-1 Therapy Offers Opportunity to Sequence Agents
https://www.onclive.com/view/targeted-pd-1-therapy-offers-opportunity-to-sequence-agents

Oct 6th, 2021 - Jeffrey S. Weber, MD, PhD Director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center and Research Institute, Tampa, FL Drugs that target the programmed death-1 (PD-1) pathway hold considerable promise for the t...

see more →

Patient Education  6 results see all →